Biomedical Diligence

Physician + engineer diligence.
Sourced to the record.

Full reports are reviewed by a practicing physician (P&T Committee Chair) and a biomedical engineer — two lenses on the same record.

Vantage reads the clinical, regulatory and commercial record on a company across devices, therapeutics, diagnostics and digital health, and puts what it finds in front of you with each factual claim linked to its source — faster and at lower cost than assembling it by hand.

See a sample evaluation License Vantage for your fund
24–48h
Quick Screen 24h · full reports 48h
34
Public data sources, including FDA, SEC and CMS
3,900+
Biomedical companies in our substrate
Latest
Medicare is rewiring breakthrough-device coverage — what RAPID means for diligence→ The cap table is a legal document, not just a math problem→ Founders from the incumbent: an asset and a liability→

Not sure where to start?

Select your role to see solutions tailored to you

VC / Angel Investor

Screening healthcare deals for investment

PE Healthcare

Evaluating platform or add-on acquisitions

Corporate M&A

Assessing strategic acquisition targets

Technology Transfer Office

Commercializing university innovations

Incubator / Accelerator

De-risking portfolio companies

Founder (raising)

Get investor-ready before your round

Screening a Pipeline

One Company or a Whole Pipeline

Run a Quick Screen on each company in your pipeline: six independent signals per company, each linked to its source records, with no composite score and no ranking verdict. Funds that screen regularly can license Vantage instead.

Pipeline screening Fund licenses
8
Diligence Domains
4
Life Science Verticals
3,900+
Companies in Our Substrate
24–48h
Turnaround
34
Public Data Sources

Coverage

Four Verticals

Each vertical has its own regulatory pathways, public records and reimbursement questions.

Medical Devices

510(k), De Novo and PMA records, recalls, reimbursement coding and comparable companies.

Diagnostics

IVD clearances and approvals, laboratory-developed tests, coverage and coding.

Therapeutics

Drug and biologic approvals, trial registries, patents and exclusivity.

Digital Health

Software as a medical device, AI-enabled devices, clinical evidence and reimbursement.

Depth of Analysis

See What Standard Due Diligence Misses

A physician and an engineer read the record layer by layer — the clinical, technical and regulatory questions a financial review is not built to ask.

Most Due Diligence Stops at the Surface

Standard VC and PE diligence is often led by generalists reviewing pitch decks, financials and team bios. That review catches a great deal, but it is not built to read clinical evidence, regulatory history or manufacturing and quality records the way a physician or an engineer does.

Vantage full reports add those layers. Our physician chairs a hospital P&T committee that reviews drugs and devices for adoption. Our engineer brings 10+ years of manufacturing, quality and reliability engineering at St. Jude Medical, Masimo and Axonics.

The deepest layer — where clinical and technical questions meet — is where reading with both lenses adds the most.

01Surface
Standard Due DiligenceMBA / Finance / Legal
✓ Pitch deck ✓ Financials ✓ Cap table ✓ Team bios ✓ Market size
Reviewed
02Clinical
Physician-Led ReviewMD / Clinical Specialist
✓ Regulatory pathway ⚠ Clinical evidence gaps ✓ Safety profile ⚠ Adoption barriers ✓ Unmet need
2 risks found
03Technical
Engineering ReviewBME / Manufacturing
✓ IP landscape ⚠ Scale-up risk ⚠ Quality gaps ✓ Design maturity ✓ Supply chain
2 risks found
04Deep
Clinical-Technical IntersectionMD + BME Combined
✕ Reimbursement misalignment ✕ Regulatory-manufacturing conflict ⚠ Competitive timing ✕ Hidden predicate risk
3 critical risks
Clear
Risk found
Critical

Illustrative example, not a real company.

Why Vantage

Different by design — and built to be trusted

The same diligence a senior physician and a biomedical engineer would run on your company — delivered faster and at lower cost than your realistic alternative, with factual claims linked to their sources.

How we compare Vantage Generalist consultant Market-research report Generic AI tool
Turnaround 24–48 hours Typically weeks Off-the-shelf Instant
Cost $5,000–$25,000 per report Typically higher Varies (not company-specific) Low
Physician + biomedical-engineer dual lens ✓ ✗ ✗ ✗
Factual claims linked to their sources ✓ Partial Partial Can invent specifics
Compared against 3,900+ biomedical companies in a multi-source substrate ✓ ✗ ✗ ✗

Sources you can check.

Factual claims in a Vantage report are linked to their source — an FDA record, an SEC filing, a ClinicalTrials.gov entry, a USPTO patent, a CMS coverage document, or the materials you provided. Before a report is released, automated checks look for identifiers, trials and comparables that do not match a real record, and where the record is thin, the report says so. As generic AI diligence floods the market, output you can check before you stake a decision on it is what matters.

We don’t forecast winners. We make the knowable risks legible.

Vantage doesn’t claim to predict which companies succeed — early-stage outcomes turn on execution and luck no dataset can price. What we do is make the clinical, regulatory, and commercial risks that are knowable today legible, each one linked to its source. Where a generic AI tool can invent a 510(k) number or a trial to fill a gap, we check identifiers against the real FDA, SEC, ClinicalTrials.gov, USPTO or CMS record — and where the record is thin, the report says so.

Four-Tier Pricing

Pick the depth that fits the decision

Every tier is a flat fee. Start with a Quick Screen, scale to deeper diligence when the decision demands it.

Triage

Quick Screen

Automated first read on one company, for screening and first-pass diligence.

$5,000
24 hours after a complete intake
  • Six independent signals
  • Each linked to its source records
  • No composite score or verdict
  • Fee credits toward a full report
See the Quick Screen
Founders

Founder Report

Eight-domain diligence on your own company, reviewed by a physician and a biomedical engineer: what an investor’s diligence will surface, before they run it.

$7,500
48-hour turnaround
  • Eight domains, 28 sections
  • Comparable companies from public records
  • Physician and engineer review
  • 30-min debrief
Get Founder Report

University TTO or incubator? See the TTO and Incubator reports.

Investor Flagship

Diligence Report

Full diligence read on a single company for an investment decision.

$20,000
48-hour turnaround
  • Eight domains with cohort comparables
  • Claims cited to their source records
  • Physician and engineer review
  • MD debrief; fee credits toward a License
Book a Call
Corporate / M&A

M&A Report

Target evaluation for corporate development and BD.

$25,000
48-hour turnaround
  • Everything in the Diligence Report
  • Integration risk
  • Reference-contact review
  • 60-min strategy session
Book a Call

Also available: the Complete Package ($15,000) and TTO and Incubator Reports ($7,500 each). Compare all reports · Screening a whole pipeline? See Deal Flow and fund licenses.

Methodology, stress-tested in public

Most diligence reports describe the company. Ours reads it the way a hospital P&T committee reads a new drug or device before adoption — and you can see the framework applied, in public, to retrospectives on Theranos, Exactech, Pear and Owlet.

Read the public retrospectives → · See a sample report →

Our Team

MD + Engineer Partnership

Two complementary perspectives: clinical rigor and technical depth. Founded by Arvind Ravinutala, MD, a practicing physician, and Aswini Ravinutala, BME, a biomedical engineer. Specialist consultation is available when an engagement needs it.

Arvind Ravinutala, MD

Arvind Ravinutala

Co-Founder & Managing Partner
MD | Practicing Physician | P&T Committee Chair

Practicing physician and Chair of a hospital Pharmacy & Therapeutics (P&T) Committee, which reviews drugs and devices for adoption. 14+ years of clinical, operational, academic and entrepreneurial leadership. Leads clinical and regulatory review on full reports.

Aswini Ravinutala

Aswini Ravinutala

Co-Founder & Partner
BME | Biomedical Engineer | R&D Manager, Spiro Medical

Biomedical engineer with 10+ years in medical devices: manufacturing, quality and reliability engineering at St. Jude Medical and Masimo, and operations engineering and management at Axonics through its 2024 acquisition by Boston Scientific (Boston Scientific, 2024). R&D Manager at Spiro Medical. Leads technical, manufacturing and quality review on full reports.

Beyond the Founders

Specialist consultation is available when an engagement needs it — for example, a clinical specialty or a regulatory question outside our own depth — and is described in the engagement terms when it is used.

From Our Diligence Desk

Latest Insights

Practitioner takes on the risks standard diligence misses — regulatory, clinical, reimbursement, and deal structure.

FDA authorization RAPID (proposed) · as soon as ~2 monthsCoverage Standard path · longer, evidence-heavyCoverage
LatestReimbursement · Policy Watch

Medicare Is Rewiring Breakthrough-Device Coverage — What RAPID Means for Diligence

CMS's proposed RAPID pathway, the paused TCET program and the finalized repeal of NTAP's Breakthrough alternative pathway are redrawing device reimbursement in 2026. What it means for your diligence, and the questions to ask now.

Read the analysis →
Deal Structure

The Cap Table Is a Legal Document, Not Just a Math Problem

Liquidation preferences, SAFE conversions, and anti-dilution move the return waterfall more than the headline valuation.

Read More → Team & IP

Founders From the Incumbent: An Asset and a Liability

Deep domain depth comes with prior-employer IP, non-compete, and trade-secret exposure. How to diligence both sides.

Read More → Regulatory

510(k) Predicate Strategy: How to Pick One That Survives Diligence

How to choose a 510(k) predicate that holds up in diligence, checked against public FDA data.

Read More →
See all insights

Ready to Move Forward?

Start with a Quick Screen and see what Vantage can do for your due diligence, investment thesis, or strategic decision.

See the Quick Screen

Before you go...

An automated Quick Screen for $5,000: six independent signals on one company, each linked to its source records, within 24 hours of a complete intake.

See the Quick Screen